Published in Mod Pathol on March 01, 2004
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun (2016) 2.22
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology (2012) 1.54
Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol (2007) 1.44
Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol (2007) 1.39
Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol (2008) 1.26
Prognostic value of discs large homolog 7 transcript levels in prostate cancer. PLoS One (2013) 1.12
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
Prognostic factors in prostate cancer. Diagn Pathol (2006) 0.99
Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One (2011) 0.99
Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem (2012) 0.97
Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl (2009) 0.96
Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases. J Pathol Inform (2016) 0.90
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics (2009) 0.90
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci (2016) 0.86
The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas. Front Physiol (2016) 0.86
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. Br J Cancer (2012) 0.84
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics (2008) 0.84
Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy. Prostate Int (2013) 0.83
Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer. Prostate (2012) 0.82
The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2009) 0.82
Prognostic value of nuclear matrix protein expression in localized prostate cancer. J Cancer Res Clin Oncol (2012) 0.81
Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One (2014) 0.81
Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl (2016) 0.81
Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. Cancer Biol Ther (2011) 0.80
Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System. J Cancer (2016) 0.79
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget (2016) 0.78
A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Mol Oncol (2016) 0.78
Comparison study of distinguishing cancerous and normal prostate epithelial cells by confocal and polarization diffraction imaging. J Biomed Opt (2016) 0.78
[Prognostic factors in prostate cancer]. Pathologe (2005) 0.78
Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget (2017) 0.78
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics (Basel) (2016) 0.77
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma. Med Sci Monit (2012) 0.77
Diagnosis of prostate cancer via nanotechnological approach. Int J Nanomedicine (2015) 0.77
Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus) anterior prostate. Oncol Lett (2015) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Gene panel model predictive of outcome in patients with prostate cancer. OMICS (2013) 0.76
Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer. Cancer Med (2012) 0.76
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
[Gleason grading: diagnostic criteria and clinical implications]. Pathologe (2005) 0.75
Salvage radiation therapy 11 years after a radical prostatectomy. Can Urol Assoc J (2016) 0.75
Automated prostate tissue referencing for cancer detection and diagnosis. BMC Bioinformatics (2016) 0.75
Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. PLoS One (2015) 0.75
Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart center. Int J Clin Exp Pathol (2013) 0.75
Constitutive and Inducible Expression of Invasion-related Factors in PC-3 Prostate Cancer Cells. J Cancer Prev (2015) 0.75
Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer. Oncotarget (2017) 0.75
Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. Curr Genomics (2017) 0.75
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel) (2017) 0.75
Metastatic phenotype in CWR22 prostate cancer xenograft following castration. Prostate (2015) 0.75
Response to (223)Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report. Oncol Lett (2016) 0.75
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer (2017) 0.75
MicroRNA‑361‑5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non‑small cell lung cancer. Mol Med Rep (2015) 0.75
The evolving Gleason grading system. Chin J Cancer Res (2016) 0.75
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer. Med Sci Monit (2017) 0.75
Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men. J Hum Genet (2016) 0.75
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia. Prostate Int (2013) 0.75
A study to correlate histopathology, biochemical marker and immunohistochemical expression of sex-steroid receptors in prostatic growth. Indian J Med Paediatr Oncol (2014) 0.75
Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection. Oncoscience (2016) 0.75
Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget (2017) 0.75
MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology. J Magn Reson Imaging (2017) 0.75
Gland segmentation in prostate histopathological images. J Med Imaging (Bellingham) (2017) 0.75
Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol (2016) 0.75
Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: comparison with Gleason scores. MAGMA (2016) 0.75
Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44(+)CD24(-) stemness. Oncotarget (2017) 0.75
CXXC5 expression in prostate cancer: implications for cancer progression. Int J Exp Pathol (2017) 0.75